GT200500310A - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
GT200500310A
GT200500310A GT200500310A GT200500310A GT200500310A GT 200500310 A GT200500310 A GT 200500310A GT 200500310 A GT200500310 A GT 200500310A GT 200500310 A GT200500310 A GT 200500310A GT 200500310 A GT200500310 A GT 200500310A
Authority
GT
Guatemala
Prior art keywords
organic compounds
proliferative diseases
camptotecine
topoisomerase
inhibitor
Prior art date
Application number
GT200500310A
Other languages
English (en)
Inventor
Isabel Ottinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35691476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200500310(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200500310A publication Critical patent/GT200500310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Abstract

LA PRESENTE INVENCIÓN SE REALACIONA CON NUEVAS COMPOSICIONES FARMACÉUTICAS EN LAS CUALES EL INGREDIENTE ACTIVO ES UN INHIBIDOR DE LA TOPOISOMERASA I, EN PARTICULAR UN DERIVADO DE LA CAMPTOTECINA, QUE ES ÚTIL PARA EL TRATAMIENTO Y PREVENCIÓN DE ENFERMEDADES PROLIFERATIVAS COMO EL CÁNCER.
GT200500310A 2004-11-19 2005-10-28 Compuestos organicos GT200500310A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62975704P 2004-11-19 2004-11-19

Publications (1)

Publication Number Publication Date
GT200500310A true GT200500310A (es) 2006-06-19

Family

ID=35691476

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500310A GT200500310A (es) 2004-11-19 2005-10-28 Compuestos organicos

Country Status (28)

Country Link
US (1) US8518961B2 (es)
EP (1) EP1814520B1 (es)
JP (1) JP4982378B2 (es)
KR (1) KR101283840B1 (es)
CN (1) CN101056619A (es)
AR (1) AR052033A1 (es)
AU (1) AU2005306018B2 (es)
BR (1) BRPI0518448A2 (es)
CA (1) CA2584343C (es)
DK (1) DK1814520T3 (es)
ES (1) ES2572133T3 (es)
GT (1) GT200500310A (es)
HR (1) HRP20160446T1 (es)
HU (1) HUE027135T2 (es)
IL (1) IL182703A (es)
MA (1) MA29076B1 (es)
MX (1) MX2007005897A (es)
MY (1) MY148647A (es)
NO (1) NO342592B1 (es)
NZ (1) NZ554551A (es)
PE (1) PE20061077A1 (es)
PL (1) PL1814520T3 (es)
RU (3) RU2007122470A (es)
SI (1) SI1814520T1 (es)
TN (1) TNSN07193A1 (es)
TW (1) TWI368521B (es)
WO (1) WO2006053755A1 (es)
ZA (1) ZA200703148B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
AR055602A1 (es) * 2005-08-10 2007-08-29 Novartis Ag Una composicion farmaceutica de microparticulas de 7-terbutoxi-imino-metil-camptotecina
WO2008055146A2 (en) * 2006-10-31 2008-05-08 Wyeth Formulations of phospholipase enzyme inhibitors
US20100070052A1 (en) * 2008-08-19 2010-03-18 Robb Fujioka System and method for providing applications and peripherals to a fixed price component-based computing platform
MX340819B (es) * 2010-06-29 2016-07-26 Poniard Pharmaceuticals Inc * Formulacion oral de inhibidores de quinasa.
CN103168037A (zh) 2010-06-30 2013-06-19 博尼亚德医药品股份有限公司 激酶抑制剂的合成和用途
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP3897589A4 (en) * 2018-12-19 2022-10-12 Corcept Therapeutics Incorporated PHARMACEUTICAL FORMULATIONS CONTAINING A RELACORILANT, AN AZADECALIN COMPOUND FUSED WITH A HETEROARYL KETONE
WO2024042523A1 (en) * 2022-08-24 2024-02-29 Lyotropic Delivery Systems Ltd. Oral delivery of active compounds for treating glycogen storage diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
CA2151491A1 (en) 1992-12-24 1994-07-07 Robert J. Kaufman Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO1999006024A1 (en) 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
CA2331640A1 (en) 1998-05-07 1999-11-11 Elan Corporation Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
DK1044977T3 (da) * 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
AU5273200A (en) 1999-05-24 2000-12-12 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US20020150615A1 (en) * 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
US20030087837A1 (en) 2001-10-15 2003-05-08 Jonas Jeffrey M. Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
AU2002353118A1 (en) 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) * 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) * 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
CA2543722C (en) * 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CA2537029C (en) * 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
CA2548078C (en) 2003-12-17 2009-05-12 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
IL182703A0 (en) 2007-09-20
PE20061077A1 (es) 2006-11-13
PL1814520T3 (pl) 2016-08-31
EP1814520B1 (en) 2016-04-13
RU2012120388A (ru) 2013-11-27
RU2007122470A (ru) 2008-12-27
CA2584343C (en) 2013-09-24
SI1814520T1 (sl) 2016-06-30
EP1814520A1 (en) 2007-08-08
NO342592B1 (no) 2018-06-18
MY148647A (en) 2013-05-15
AR052033A1 (es) 2007-02-28
JP2008520606A (ja) 2008-06-19
BRPI0518448A2 (pt) 2008-11-18
CA2584343A1 (en) 2006-05-26
US20080125450A1 (en) 2008-05-29
TWI368521B (en) 2012-07-21
RU2015131700A (ru) 2017-02-02
KR20070084357A (ko) 2007-08-24
WO2006053755A1 (en) 2006-05-26
TNSN07193A1 (en) 2008-11-21
AU2005306018B2 (en) 2009-12-17
KR101283840B1 (ko) 2013-07-15
JP4982378B2 (ja) 2012-07-25
TW200631606A (en) 2006-09-16
IL182703A (en) 2015-11-30
CN101056619A (zh) 2007-10-17
MA29076B1 (fr) 2007-12-03
NO20072258L (no) 2007-08-10
DK1814520T3 (en) 2016-05-30
MX2007005897A (es) 2007-06-19
ES2572133T3 (es) 2016-05-30
NZ554551A (en) 2010-01-29
HRP20160446T1 (hr) 2016-05-20
HUE027135T2 (en) 2016-08-29
RU2620331C2 (ru) 2017-05-24
US8518961B2 (en) 2013-08-27
AU2005306018A1 (en) 2006-05-26
ZA200703148B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
GT200500310A (es) Compuestos organicos
ECSP066717A (es) Compuestos de quinolina sustituidos
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
ECSP10010112A (es) Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
MX2008005853A (es) Mezclas insecticidas sinergicas para el tratamiento de las semillas
AR062448A1 (es) Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
CU23831B1 (es) Compuestos de pirrolo-pirimidina
GT200900027A (es) Compuestos organicos
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
UY31457A1 (es) Derivados acidos de cicloalquilamino
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
ECSP088922A (es) Derivados de amino-tiazol y sus usos como agentes antibacterianos
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
UY30675A1 (es) Metodos para el tratamiento de la depresion